Acth
(corticotropin)PreclinicalSmall molecule
Acth is one of 45 small molecule programs targeting Septic Shock. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
44
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Septic Shock
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Pitressin
AAultman Health Foundation
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Zocor
OOrganon and Co
Approved
Florinef
Jazz PharmaceuticalsPhase 3
Carnitor
LLeadiant Biosciences, Inc.
Approved
Methylthioninium Chloride
PProvepharm SAS
Phase 3
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapiblyk
AAultman Health Foundation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
ACTH
NDA NDA008317
Jan 1, 1982
ACTHAR
NDA NDA007504
Jan 1, 1982
ACTHAR GEL
NDA NDA008372
Jan 1, 1982
CORTICOTROPIN
NDA NDA010831
Jan 1, 1982
PURIFIED CORTROPHIN GEL
NDA NDA008975
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for corticotropin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Acth. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIstituto Clinico Humanitas